Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
176 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Diabetic Macular Edema - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2014', provides an overview of the Diabetic Macular Edema's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diabetic Macular Edema Overview 8 Therapeutics Development 9 Pipeline Products for Diabetic Macular Edema - Overview 9 Pipeline Products for Diabetic Macular Edema - Comparative Analysis 10 Diabetic Macular Edema - Therapeutics under Development by Companies 11 Diabetic Macular Edema - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Diabetic Macular Edema - Products under Development by Companies 18 Diabetic Macular Edema - Companies Involved in Therapeutics Development 21 ActiveSite Pharmaceuticals, Inc. 21 Acucela Inc. 22 Aerpio Therapeutics, Inc. 23 Allergan, Inc. 24 AlphaMab Co., Ltd 25 Ampio Pharmaceuticals, Inc. 26 Astellas Pharma Inc. 27 Auven Therapeutics Management L.L.L.P 28 Avalanche Biotechnologies, Inc. 29 Eleven Biotherapeutics Inc. 30 F. Hoffmann-La Roche Ltd. 31 Foamix Pharmaceuticals Ltd. 32 Gene Signal International SA 33 Genmab A/S 34 GlaxoSmithKline plc 35 iCo Therapeutics Inc. 36 Icon Bioscience, Inc. 37 Kala Pharmaceuticals, Inc. 38 Kowa Company, Ltd. 39 Mabion SA 40 MacuCLEAR, Inc. 41 Molecular Design International, Inc. 42 NicOx S.A. 43 Ohr Pharmaceutical Inc. 44 Pfizer Inc. 45 Quark Pharmaceuticals, Inc. 46 Regeneron Pharmaceuticals, Inc. 47 Santen Pharmaceutical Co., Ltd. 48 Senju Pharmaceutical Co., Ltd. 49 ThromboGenics NV 50 Diabetic Macular Edema - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 55 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 49-B - Drug Profile 62 abicipar pegol - Drug Profile 64 aflibercept (recombinant) - Drug Profile 66 aganirsen - Drug Profile 69 AKB-9778 - Drug Profile 71 ALG-1001 - Drug Profile 73 ASP-440 - Drug Profile 75 AVA-101 - Drug Profile 77 conbercept - Drug Profile 79 danazol - Drug Profile 81 darapladib - Drug Profile 82 dexamethasone dipropionate - Drug Profile 84 difluprednate - Drug Profile 85 Drug for Diabetic Macular Edema - Drug Profile 86 Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile 87 EBI-029 - Drug Profile 88 emixustat hydrochloride - Drug Profile 89 iCo-007 - Drug Profile 91 KVD-001 - Drug Profile 92 loteprednol etabonate - Drug Profile 94 MC-4001 - Drug Profile 95 minocycline Gel - Drug Profile 96 NCX-422 - Drug Profile 97 NCX-434 - Drug Profile 98 nesvacumab - Drug Profile 99 ocriplasmin (recombinant) - Drug Profile 101 Peptide for Diabetic Macular Edema - Drug Profile 104 PF-04634817 - Drug Profile 105 PF-655 - Drug Profile 106 Protein for Diabetic Macular Edema - Drug Profile 108 ranibizumab - Drug Profile 109 ranibizumab biosimilar - Drug Profile 112 ranibizumab biosimilar - Drug Profile 113 ripasudil - Drug Profile 114 RX-10045 - Drug Profile 115 Small Molecule to Inhibit Kallikrein for AMD and DME - Drug Profile 117 Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema - Drug Profile 118 squalamine lactate - Drug Profile 119 teprotumumab - Drug Profile 122 Diabetic Macular Edema - Recent Pipeline Updates 124 Diabetic Macular Edema - Dormant Projects 162 Diabetic Macular Edema - Discontinued Products 163 Diabetic Macular Edema - Product Development Milestones 164 Featured News & Press Releases 164 Appendix 172 Methodology 172 Coverage 172 Secondary Research 172 Primary Research 172 Expert Panel Validation 172 Contact Us 173 Disclaimer 173
List of Tables Number of Products under Development for Diabetic Macular Edema, H2 2014 12 Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Comparative Analysis by Late Stage Development, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Comparative Analysis by Unknown Stage Development, H2 2014 20 Products under Development by Companies, H2 2014 21 Products under Development by Companies, H2 2014 (Contd..1) 22 Products under Development by Companies, H2 2014 (Contd..2) 23 Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2014 24 Diabetic Macular Edema - Pipeline by Acucela Inc., H2 2014 25 Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H2 2014 26 Diabetic Macular Edema - Pipeline by Allergan, Inc., H2 2014 27 Diabetic Macular Edema - Pipeline by AlphaMab Co., Ltd, H2 2014 28 Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 29 Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H2 2014 30 Diabetic Macular Edema - Pipeline by Auven Therapeutics Management L.L.L.P, H2 2014 31 Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H2 2014 32 Diabetic Macular Edema - Pipeline by Eleven Biotherapeutics Inc., H2 2014 33 Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 34 Diabetic Macular Edema - Pipeline by Foamix Pharmaceuticals Ltd., H2 2014 35 Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2014 36 Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2014 37 Diabetic Macular Edema - Pipeline by GlaxoSmithKline plc, H2 2014 38 Diabetic Macular Edema - Pipeline by iCo Therapeutics Inc., H2 2014 39 Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H2 2014 40 Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 41 Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H2 2014 42 Diabetic Macular Edema - Pipeline by Mabion SA, H2 2014 43 Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H2 2014 44 Diabetic Macular Edema - Pipeline by Molecular Design International, Inc., H2 2014 45 Diabetic Macular Edema - Pipeline by NicOx S.A., H2 2014 46 Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H2 2014 47 Diabetic Macular Edema - Pipeline by Pfizer Inc., H2 2014 48 Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 49 Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 50 Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 51 Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2014 52 Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2014 53 Assessment by Monotherapy Products, H2 2014 54 Number of Products by Stage and Target, H2 2014 56 Number of Products by Stage and Mechanism of Action, H2 2014 59 Number of Products by Stage and Route of Administration, H2 2014 62 Number of Products by Stage and Molecule Type, H2 2014 64 Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H2 2014 127 Diabetic Macular Edema - Dormant Projects, H2 2014 165 Diabetic Macular Edema - Discontinued Products, H2 2014 166
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
